| abstract |
The discovery of a new form of 12-lipoxygenase RNA and protein in human adrenal, mononuclear, vascular smooth muscle and endothelial cells is disclosed. Activation of this 12-LO pathway mediates angiotensin II and glucose induced vascular and renal actions. A rationale for the development of pharmaceutical or molecular methods to inhibit this newly discovered lipoxygenase pathway is described. |